Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Healthtrust
Cipla
Teva
US Department of Justice
Novartis
Julphar
Express Scripts
Fish and Richardson
AstraZeneca

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,212,155

« Back to Dashboard

Summary for Patent: 5,212,155

Title: Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
Abstract:This invention provides a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal a transplant rejection inhibiting amount of rapamycin. Also disclosed is a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal (a) an amount of rapamycin in combination with (b) an amount of one or more other chemotherapeutic agents for inhibiting transplant rejection, e.g., azathioprine, corticosteroids, cyclosporin and FK506, said amounts of (a) and (b) together being effective to inhibit transplant rejection and to maintain inhibition of transplant rejection.
Inventor(s): Calne; Roy (Cambridge, GB2)
Assignee:
Application Number:07/738,960
Patent Claim Types:
see list of patent claims
Use; Delivery;

No matches for this query

International Patent Family for Patent: 5,212,155

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany10199045► Subscribe
Germany69025803► Subscribe
Denmark0401747► Subscribe
European Patent Office0401747► SubscribeCA 2001 00025Denmark► Subscribe
European Patent Office0401747► SubscribeSPC/GB01/036United Kingdom► Subscribe
European Patent Office0401747► Subscribe25/2001Austria► Subscribe
Spain2085299► Subscribe
Greece3019792► Subscribe
Hong Kong1005704► Subscribe
Hungary903487► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
Julphar
US Army
UBS
Federal Trade Commission
Queensland Health
Covington
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot